Impaired medullary circulation and direct toxicity due to a drug metabolite seem to play a critical role in inducing interstitial fibrosis, which can be facilitated by a sustained
production of some growth factors and cytokines.
The result is an accumulation of senescent cells, which causes inflammation, tissue degradation and
the production of growth factors that alter the tissue microenvironment, leading to disease.
Not exact matches
Important
factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our
growth strategy, including the timing, execution, and profitability
of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring
production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost
of accommodating, announced increases in the build rates
of certain aircraft; 6) the effect on aircraft demand and build rates
of changing customer preferences for business aircraft, including the effect
of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result
of global economic uncertainty or otherwise; 8) the effect
of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution
of key milestones such as the receipt
of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation
of our announced acquisition
of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability
of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk
of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus»
production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts
of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak
of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact
of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition
of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect
of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect
of changes in tax law, such as the effect
of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations
of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect
of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability
of raw materials and purchased components; 23) our ability to recruit and retain a critical mass
of highly - skilled employees and our relationships with the unions representing many
of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment
of interest on, and principal
of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness
of any interest rate hedging programs; 28) the effectiveness
of our internal control over financial reporting; 29) the outcome or impact
of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition
of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result
of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks
of doing business internationally, including fluctuations in foreign current exchange rates, impositions
of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.
Such risks, uncertainties and other
factors include, without limitation: (1) the effect
of economic conditions in the industries and markets in which United Technologies and Rockwell Collins operate in the U.S. and globally and any changes therein, including financial market conditions, fluctuations in commodity prices, interest rates and foreign currency exchange rates, levels
of end market demand in construction and in both the commercial and defense segments
of the aerospace industry, levels
of air travel, financial condition
of commercial airlines, the impact
of weather conditions and natural disasters and the financial condition
of our customers and suppliers; (2) challenges in the development,
production, delivery, support, performance and realization
of the anticipated benefits
of advanced technologies and new products and services; (3) the scope, nature, impact or timing
of acquisition and divestiture or restructuring activity, including the pending acquisition
of Rockwell Collins, including among other things integration
of acquired businesses into United Technologies» existing businesses and realization
of synergies and opportunities for
growth and innovation; (4) future timing and levels
of indebtedness, including indebtedness expected to be incurred by United Technologies in connection with the pending Rockwell Collins acquisition, and capital spending and research and development spending, including in connection with the pending Rockwell Collins acquisition; (5) future availability
of credit and
factors that may affect such availability, including credit market conditions and our capital structure; (6) the timing and scope
of future repurchases
of United Technologies» common stock, which may be suspended at any time due to various
factors, including market conditions and the level
of other investing activities and uses
of cash, including in connection with the proposed acquisition
of Rockwell; (7) delays and disruption in delivery
of materials and services from suppliers; (8) company and customer - directed cost reduction efforts and restructuring costs and savings and other consequences thereof; (9) new business and investment opportunities; (10) our ability to realize the intended benefits
of organizational changes; (11) the anticipated benefits
of diversification and balance
of operations across product lines, regions and industries; (12) the outcome
of legal proceedings, investigations and other contingencies; (13) pension plan assumptions and future contributions; (14) the impact
of the negotiation
of collective bargaining agreements and labor disputes; (15) the effect
of changes in political conditions in the U.S. and other countries in which United Technologies and Rockwell Collins operate, including the effect
of changes in U.S. trade policies or the U.K.'s pending withdrawal from the EU, on general market conditions, global trade policies and currency exchange rates in the near term and beyond; (16) the effect
of changes in tax (including U.S. tax reform enacted on December 22, 2017, which is commonly referred to as the Tax Cuts and Jobs Act
of 2017), environmental, regulatory (including among other things import / export) and other laws and regulations in the U.S. and other countries in which United Technologies and Rockwell Collins operate; (17) the ability
of United Technologies and Rockwell Collins to receive the required regulatory approvals (and the risk that such approvals may result in the imposition
of conditions that could adversely affect the combined company or the expected benefits
of the merger) and to satisfy the other conditions to the closing
of the pending acquisition on a timely basis or at all; (18) the occurrence
of events that may give rise to a right
of one or both
of United Technologies or Rockwell Collins to terminate the merger agreement, including in circumstances that might require Rockwell Collins to pay a termination fee
of $ 695 million to United Technologies or $ 50 million
of expense reimbursement; (19) negative effects
of the announcement or the completion
of the merger on the market price
of United Technologies» and / or Rockwell Collins» common stock and / or on their respective financial performance; (20) risks related to Rockwell Collins and United Technologies being restricted in their operation
of their businesses while the merger agreement is in effect; (21) risks relating to the value
of the United Technologies» shares to be issued in connection with the pending Rockwell acquisition, significant merger costs and / or unknown liabilities; (22) risks associated with third party contracts containing consent and / or other provisions that may be triggered by the Rockwell merger agreement; (23) risks associated with merger - related litigation or appraisal proceedings; and (24) the ability
of United Technologies and Rockwell Collins, or the combined company, to retain and hire key personnel.
The looming supply
growth is mostly due to two
factors: the scheduled end
of OPEC / non-OPEC
production cuts in March and US shale
production, including NGLs, «growing like crazy,» said New York - based Mike Wittner, managing director and global head
of oil research at Societe Generale.
Furthermore, guidance for total
production doesn't
factor in much
growth, and the low end
of the range would in fact be a reduction in output.
As a result
of these
factors, Pioneer expects
production growth to come in at the low end
of its 15 % - to - 18 % guidance range for the year, while oil as a percentage
of total
production will be 58 % instead
of the 62 % it expected.
This
factor took a back seat during the oil price rally in recent months, but with
production growth of nearly 850,000 barrels per day since late in the summer, U.S. oil producers have demonstrated how aggressive they can be in a rising price environment.
Studies show that a Ketogenic Diet can increase the
production of brain derived neurotropic
factor (BDNF), an anti-inflammatory protein that promotes the
growth of nerves.1
Dr Akoto said the smuggling
of cocoa and its subsidised inputs into neighbouring countries as a direct consequence
of the input distribution system and the product pricing policies
of the government, as well as the refusal
of the government to pay annual
production bonuses to farmers, was the other
factor inhibiting
growth in the cocoa sub-sector.
GHRH boosts
production of growth hormone and insulin - like
growth factor - 1, both
of which build muscle.
But recent research has linked their long term use to various unwanted effects, including pneumonia, heart attack, and bone fracture, they point out, adding that PPIs are known to stimulate the
production of gastrin, a powerful
growth factor.
«Considering the large portion
of the green industry involved with growing plants in containers and the importance
of understanding the physiology and morphology
of roots, the
factors that influence root
growth in container
production should be continually investigated,» they wrote.
This happens because the loss
of blood flow in a vessel causes the local oxygen level to drop, which stimulates local
production of vascular endothelial
growth factor, or VEGF, a protein which in most tissues causes the
growth of new blood vessels to repair damage.
These long - lived worms had mutations that decreased the
production of a protein known as insulinlike
growth factor 1 (IGF - 1), which helps drive cellular
growth and division.
Demonstrating Cpf1's noticeable specificity, another research team from the same IBS Center succeeded in bringing Cpf1 RNP - mediated mutations into mouse embryos: The researchers targeted Foxn1 (a transcription
factor that regulates the immune system, including the
growth of skin hairs), as well as Tyrosinase (an enzyme that catalyzes the
production of melanin, a natural pigment that determines the color
of skin).
The new test instead looks for hGH's knock - on effects in the body — namely, increased
production of insulin - like
growth factor 1 (IGF - 1) and a substance called P3NP.
Abnormal and uncontrolled
production of this class
of proteins, known as transcription
factors, allow for cells to bypass
growth control mechanisms and to develop characteristics necessary for invading surrounding tissues.
«BDNF is a basic
growth factor and it's related to neurogenesis, the
production of new neurons,» Barbey said.
So Hoffman is now looking for leads among genes controlling the
production of molecules called
growth factors, which regulate cell
growth and division.
Compared to their unmodified counterparts, the
growth factors containing the PIGF - 2 sequence resulted in much faster wound closing and
production of granulation tissue, and also led to a more pronounced new blood vessel formation, which is essential in sustaining the latter.
The scientists in Augustin's laboratory consequently pursued preclinical tumor therapy experiments, which were aimed at not just blocking angiogenesis, but to also suppress the
production of tumor - promoting
growth factors in endothelial cells.
These analyses showed that Angiopoietin - 2 is not just affecting angiogenesis, but controls at the same time the
production of tumor promoting
growth factors in endothelial cells.
In addition to providing a platform for studying the processes that regulate platelet
production and related diseases, the researchers hope the platelets produced can be used as a source
of growth factors for wound healing in regenerative medicine, including healing
of ulcers and burns, and stimulation
of bone tissue regeneration in dentistry and maxillofacial plastic surgery.
As a
factor of production, technology produces wealth and produces more technological progress, enabling a virtuous cycle
of exponential
growth (11, 12).
Bovine
growth hormone is also known to stimulate the
production of insulinlike
growth factor 1 (IGF1) by the liver; some studies have shown that high levels
of IGF1 in the bloodstream may heighten the risk
of prostate and breast cancers as well as a woman's chance
of conceiving twins.
In other words, during the exponential
growth that we have experienced, something produced must itself have been a
factor of production.
A relatively fixed
factor of production such as land (today we would include all natural resources) can not produce positive feedback for exponential
growth.
These include lipid lowering; protection from oxidative stress and inflammation; modification
of growth factors that can promote cancer; inhibition
of nutrient sensing pathways by amino acid restriction and gut microbiota - mediated
production of metabolites.
This happens because the loss
of blood flow in a blood vessel causes the local oxygen level to drop, which stimulates local
production of vascular endothelial
growth factor, or VEGF, a protein that in most tissues causes the
growth of new blood vessels to repair damage.
Glucose regulated protein 94 is required for muscle differentiation through its control
of the autocrine
production of insulin - like
growth factors.
Protein secretion does not always mirror mRNA levels and most workers in the field would adopt a more conservative profile
of cytokine and
growth factor production by MSC.
Hepatitis C Virus Regulates Transforming
Growth Factor [beta] 1
Production Through the Generation
of Reactive Oxygen Species in a Nuclear
Factor [kappa] B - Dependent Manner.
A major aspect
of this process is the
production of multiple angiogenic cytokines and
growth factors in response to hypoxia / ischemia, which is mediated by the transcription
factor HIF - 1 (hypoxia - inducible
factor 1).
Processes like
growth arrest are activated and others, like Initiation
factor, the starting process
of protein
production, are dramatically deactivated.
The mechanism by which human neural progenitor cells exert their effects within the retina is not wholly clear, but is likely due in part to
growth factor production [39] and possibly also to the manifestation
of some RPE - like properties.
Prior to transplantation, we analyzed the in vitro
production of specific
growth factors by unmodified hNPCctx and by hNPCctx transduced with a lentiviral gene construct designed to constitutively express GDNF (hNPCctx - GDNF)[11], [44].
Researchers find that Insulin - like
growth factor / Insulin - mediated induction
of mesodermal differentiation aids the
production of cardiac progenitor cells from embryonic stem cells towards a strategy to boost cardiac cell
production.
Inhibition
of growth,
production of insulin - like
growth factor - II (IGFII), and expression
of IGF - II mRNA
of human cancer cell lines by antagonistic analogs
of growth hormone - releasing hormone in vitro.
Furthermore, we found that human IL - 15 mediated insulin - like
growth factor - 1
production in CD215 + myeloid cells and blocking IGF - 1 reduced the tumor - promoting effect
of IL - 15.
Even more profound was a drop in insulinlike
growth factor 1 (IGF - 1), which is a biomarker for cancer
growth, and an increase in stem cell
production, which is a marker for regeneration
of cells.
Other nootropics are even capable
of stimulating the
production of nerve
growth factor where the protein synthesis ultimately results in brain cell
growth, especially in the nerve cells» dendrites which enable the communication
of electric impulses throughout the central nervous system.
Creatine's ability to increase muscular hypertrophy is derived largely from the fact that it is able to trigger creation
of new muscle cells, increase protein synthesis in the muscles and decrease the
production of myostatin which depletes muscle tissue, while at the same time increase the release
of particular hormones that promote muscle building like IGF - 1 (Insulin
Growth - like
Factor) and testosterone.
This feeding cycle stimulates the
production of cellular
factors such as Cyclic AMP or GMP, which stimulate hormone synthesis and fat burning during the day, as well as protein synthesis and
growth during the night, respectively.
Magnesium helps support the
production of brain derived neurotrophic
growth factor (BDNF) which improves the brain's ability to rewire itself.
IGF - 1 — this is the primary indicator
of growth hormone
production as GH enters the liver to stimulate the release
of insulin
growth factor 1.
What worries some experts is that about 17 %
of dairy cows are treated with the hormone rBST (or rBGH), which stimulates milk
production by increasing circulating levels
of another hormone called insulin - like
growth factor (IGF - 1).
Platelet - derived
growth factor (PDGF) in colostrum nutritionally stimulates the healthy
production of other
growth factors, including IGF - 1.
Researchers believe that a ketogenic diet reduces the
production of insulin - like
growth factor 1 (IGFT - 1), a hormone essential in the development
of the bones and the muscles
of kids and teenagers.
This Oral HGH Spray was designed to naturally stimulate the
production of human
growth hormone (HGH) and insulin - like
growth factor - 1 (IGF - 1).